TOVX catalysts
Catalysts and events linked to TOVX, newest first.
TOVX stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Theriva Biologics Publishes Phase 2b VIRAGE Pancreatic Cancer Data in Nature Medicine 2026-10-01 · Up | biotech pipeline derisking via peer-reviewed Phase 2b publication | Theriva Biologics announced the publication of Phase 2b VIRAGE trial results in Nature Medicine. | Not recorded |
| Theriva Biologics Reports Positive Phase 2b Pancreatic Cancer Data in Nature 2026-10-01 · Up | clinical pipeline validation and future partner licensing optionality | Nature Medicine published Phase 2b survival improvements for VCN-01 in metastatic pancreatic cancer. | Not recorded |
| Theriva Biologics Reports Positive Phase 2b VIRAGE Pancreatic Cancer Data in Nature 2026-10-01 · Up | clinical de-risking and pipeline valuation re-rating | Nature Medicine publication confirmed improved OS and PFS in Phase 2b pancreatic cancer trial. | Not recorded |
| Theriva Biologics VIRAGE Phase 2b Data Published in Nature Medicine 2026-10-01 · Up | clinical pipeline validation | Nature Medicine publication validates Phase 2b overall survival improvements in metastatic pancreatic cancer. | Not recorded |
| Theriva Biologics Publishes Positive VIRAGE Phase 2b Data in Nature Medicine 2026-10-01 · Up | biotech pipeline derisking via peer-reviewed Phase 2b clinical publication | Nature Medicine publication confirmed survival improvements for VCN-01 in pancreatic cancer. | Not recorded |
| Theriva Biologics Publishes Phase 2b VIRAGE data in Nature Medicine. 2026-10-01 · Up | clinical pipeline de-risking and potential partnership valuation expansion | Publication of positive Phase 2b survival data in Nature Medicine validates VCN-01 oncology platform. | Not recorded |
| Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine 2026-10-01 · Up | biotech clinical pipeline valuation repricing on positive trial publication | Nature Medicine published Phase 2b VIRAGE trial results showing improved survival metrics. | Not recorded |
| Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer Data 2026-10-01 · Up | biotech clinical pipeline de-risking via peer-reviewed survival data | Nature Medicine publication confirmed improved OS and PFS for VCN-01 in metastatic pancreatic cancer. | Not recorded |
Do these developments change your position?
Review TOVX alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-01Theriva Biologics Publishes Phase 2b Pancreatic Cancer Trial Data in Nature MedicineTOVX
- 2026-10-01Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature MedicineTOVX
- 2026-10-01Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer DataTOVX
- 2026-10-01Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer DataTOVX
- 2026-10-01Theriva Biologics Publishes Phase 2b Pancreatic Cancer Trial Data in Nature MedicineTOVX
- 2026-10-01Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Reports Positive Phase 2b Pancreatic Cancer Data in NatureTOVX
- 2026-10-01Theriva Biologics VIRAGE Phase 2b Data Published in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Publishes Positive VIRAGE Phase 2b Data in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Publishes Phase 2b VIRAGE data in Nature Medicine.TOVX
- 2026-10-01Theriva Biologics Publishes Phase 2b VIRAGE Pancreatic Cancer Data in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Reports Positive Phase 2b VIRAGE Pancreatic Cancer Data in NatureTOVX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.